Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Safety of drug-eluting beads transarterial chemoembolization under the combination therapy with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Authors
Sung-Hua Chiu
Tri-Service General Hospital, Taipei, Taiwan;
Sung-Hua Chiu , Wei-Chou Chang , Chung-Bao Hsieh , An-Chieh Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 556)
DOI
10.1200/JCO.2023.41.4_suppl.556
Abstract #
556
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).
First Author: Jemma Buchalter
Poster
2023 ASCO Annual Meeting
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
First Author: Jinpeng Li
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2023 ASCO Annual Meeting
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
First Author: Vivek Subbiah